US20190111078A1 - Pretreatment drug for t cell infusion therapy for immune-checkpoint inhibitor-resistant tumor - Google Patents

Pretreatment drug for t cell infusion therapy for immune-checkpoint inhibitor-resistant tumor Download PDF

Info

Publication number
US20190111078A1
US20190111078A1 US16/077,238 US201716077238A US2019111078A1 US 20190111078 A1 US20190111078 A1 US 20190111078A1 US 201716077238 A US201716077238 A US 201716077238A US 2019111078 A1 US2019111078 A1 US 2019111078A1
Authority
US
United States
Prior art keywords
antigen
cells
pharmaceutical composition
tumor
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/077,238
Other languages
English (en)
Inventor
Hiroshi Shiku
Naozumi Harada
Daisuke Muraoka
Kazunari Akiyoshi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mie University NUC
Kyoto University NUC
Original Assignee
Mie University NUC
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mie University NUC, Kyoto University NUC filed Critical Mie University NUC
Assigned to KYOTO UNIVERSITY, MIE UNIVERSITY reassignment KYOTO UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HARADA, NAOZUMI, SHIKU, HIROSHI, Muraoka, Daisuke, AKIYOSHI, KAZUNARI
Publication of US20190111078A1 publication Critical patent/US20190111078A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464462—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases

Definitions

  • the invention relates to a pretreatment drug that enhances the efficacy of T cell infusion therapy against immune checkpoint inhibitor-resistant tumors.
  • T cells play important roles in tumor immune response.
  • T cells recognize antigen protein-derived epitope peptides bound to major histocompatibility complex (MHC) presented on the surface of antigen presenting cells (dendritic cells, macrophages, etc.) through T cell receptors (TCR) expressed on the surface of the T cells.
  • MHC major histocompatibility complex
  • TCR T cell receptors
  • the reaction is called antigen stimulation.
  • co-stimulatory signals are generated by binding between membrane protein CD28 on the T cells and membrane protein CD80 or CD86 on the antigen presenting cells.
  • T cells are appropriately activated by TCR signals via antigen stimulation and by co-stimulatory signals.
  • CTLA-4 is expressed on activated T cells and binds to CD80 or CD86 on antigen presenting cells. As a result, the binding inhibits the binding of CD28 and CD80, or CD28 and CD86, and prevents the generation of co-stimulatory signals, and inputs inhibitory signals to T cells.
  • CTLA-4 expressed on regulatory T cells binds to CD80 or CD86 on antigen presenting cells, and thereby suppresses the activity of antigen presenting cells. Through these activities, CTLA-4 acts as an immune checkpoint molecule to suppress the activity of T cells.
  • Membrane protein PD-1 upregulated by activation of T cells is one type of immune checkpoint molecule.
  • PD-L1 is known as a ligand that binds to PD-1.
  • PD-L1 is expressed on many tumor cells and on activated immune cells.
  • TCR signals at the time of antigen stimulation are inhibited by PD-1 signals.
  • cytokine production and the cytotoxicity of T cells are reduced.
  • PD-1 signals may inhibit the proliferation and survival of T cells.
  • Immune checkpoint molecules such as CTLA-4, PD-1 and PD-L1 weaken the activity of tumor-specific T cells. As a result, these molecules are one of the main causes for tumors to evade immune responses. By inhibiting the action of CTLA-4, PD-1 or PD-L1, the activity of tumor-specific T cells can be recovered, and an immune attack against the tumor can be enhanced.
  • the use of inhibitors of immune checkpoint molecules has been evaluated in a variety of human cancers.
  • CTLA-4 inhibitory antibody and PD-1 inhibitory antibody show superior therapeutic effects, such as tumor regression and prolonged survival, in refractory melanoma, lung cancer and renal cell carcinoma patients. However, the response rate is only 20 to 30 percent in any of the cancer types. Many cancer patients are resistant to immune checkpoint inhibitors. Development of effective treatments for cancer patients who are resistant to immune checkpoint inhibitors has become an important issue in cancer treatment.
  • a combination therapy of intratumoral administration of an oncolytic virus (Newcastle disease virus) and an anti-CTLA-4 antibody shows a therapeutic effect in a nonclinical tumor model in which a mouse melanoma cell line B16F10, mouse prostate cancer cell line TRAMP-C2, or mouse colon cancer cell line CT26 is implanted subcutaneously into wild type mice. Under these conditions, the anti-CTLA-4 antibody alone does not exhibit any therapeutic effect (non-Patent Document 1).
  • a combination therapy of a tumor cell vaccine transduced with a GM-CSF gene and treated with radiation and a STING agonist and an anti-PD-1 antibody shows a therapeutic effect in a nonclinical tumor model in which a mouse melanoma cell line B16F10 or mouse colon cancer cell line CT26 is implanted subcutaneously into wild type mice. Under these conditions, the anti-PD-1 antibody does not exhibit any therapeutic effect (non-Patent Document 2).
  • a combination therapy of 4 drugs which include a DNA methylation inhibitor, a HDAC inhibitor, an anti-CTLA-4 antibody, and an anti-PD-1 antibody, shows a therapeutic effect in a nonclinical tumor model in which a mouse breast cancer cell line 4T1 is implanted subcutaneously into wild type mice.
  • Non-Patent Document 3 A combination therapy of a human Her2-specific chimeric antigen receptor (CAR)-engineered T cell infusion and an anti-PD-1 antibody shows a therapeutic effect in a nonclinical tumor model in which a murine sarcoma cell line 24JK expressing human Her2 antigen is implanted subcutaneously into a human Her2 transgenic mice. Under these conditions, the anti-PD-1 antibody alone does not exhibit any therapeutic effect (non-Patent Document 4).
  • CAR Her2-specific chimeric antigen receptor
  • non-Patent Document 5 Treatment methods shown in non-Patent Documents 1 to 4 are characterized by combining immune checkpoint inhibitors and other anti-cancer agents. These treatments are effective against tumors that express molecular targets of immune checkpoint inhibitors. However, these therapies may be less effective against tumors that do not express the molecular targets of immune checkpoint inhibitors. These results show that novel therapies are needed for tumors that do not express molecular targets of immune checkpoint inhibitors.
  • Non-Patent Document 1 Zamarin, D., et al. Sci. Transl. Med. 2014;6(226):226ra32.
  • Non-Patent Document 2 Fu, J., et al. Sci. Transl. Med. 2015;7(283):283ra52.
  • Non-Patent Document 3 Kim, K., et al. Proc. Natl. Acad. Sci. U.S.A. 2014;111(32)41774-9.
  • Non-Patent Document 4 John, L. B., et al. Clin. Cancer Res. 2013; 19(20)5636-46.
  • Non-Patent Document 5 Tumeh, P. C., et al. Nature. 2014;515 (7528)568-71.
  • An object of the invention is to provide a therapeutic technique for treating immune checkpoint inhibitor-resistant tumors. Specifically, a very effective pretreatment anti-tumor drug (antigen-loaded nanogel and immunological enhancer) combined with T cell infusion therapy is provided.
  • the present inventors have studied effective therapies for immune checkpoint inhibitor-resistant tumors in which the expression of molecular targets of immune checkpoint inhibitors is low at the tumor site.
  • a hydrophobized polysaccharide-based nanogel in which a synthetic long chain peptide antigen or a recombinant protein antigen is loaded, and an immune-enhancing agent were used.
  • the invention was completed based on the finding that infusion of antigen-specific T cells had a remarkable effect on tumors that are resistant to immune checkpoint inhibitors.
  • a pharmaceutical composition for T cell infusion therapy against an immune checkpoint inhibitor-resistant tumor which is a pharmaceutical composition to be administered prior to administration of antigen-specific T cells, comprising:
  • an antigen-loaded nanogel in which long chain peptide antigen(s) or protein antigen(s) is (are) loaded in a hydrophobized polysaccharide-based nanogel, the long chain peptide antigen(s) or protein antigen(s) containing CD8+ cytotoxic T cell recognition epitope(s) and/or CD4+ helper T cell recognition epitope(s), which is/are derived from the antigen.
  • a pharmaceutical composition for T cell infusion therapy against an immune checkpoint inhibitor-resistant tumor which is a pharmaceutical composition comprising T cells specific to said antigen to be administered after administration of said antigen-loaded nanogel, in which long chain peptide antigen(s) or protein antigen(s) is (are) loaded in a hydrophobized polysaccharide-based nanogel, the long chain peptide antigen or protein antigen containing CD8+ cytotoxic T cell recognition epitope(s) and/or CD4+ helper T cell recognition epitope(s), which is/are derived from the antigen.
  • a recombinant protein antigen can be used as the long chain peptide antigen or the protein antigen.
  • a nucleic acid having a nucleotide sequence encoding the recombinant protein that contains the predetermined amino acid sequence is prepared; after the recombinant protein is expressed by a cell (eukaryotic or prokaryotic) in which the nucleic acid has been incorporated, the recombinant protein antigen can be purified by known methods.
  • an immune-enhancing agent which is administered with the antigen-loaded nanogel, or
  • an immune-enhancing agent which is contained in the antigen-loaded nanogel.
  • composition according to any one of 1) to 5), comprising a sequence selected from the group consisting of 2 to 10 tyrosines, 2 to 10 threonines, 2 to 10 histidines, 2 to 10 glutamines and 2 to 10 asparagines between the T cell recognition epitopes in the long chain peptide antigen.
  • the immune-enhancing agent is at least one selected from the group consisting of TLR (Toll-like receptor) agonists (CpG oligo DNA or Poly-IC RNA), STING agonists or RLR (RIG-I-like receptors) agonists.
  • TLR agonist CpG oligo DNA or Poly-IC RNA
  • composition according to any one of 1) to 9), wherein the administration route of the antigen-loaded nanogel is at least one selected from the group consisting of subcutaneous, intradermal, intramuscular, intratumoral and intravenous.
  • a delivery system for selectively delivering a substance to tumor-associated macrophages when administered intravenously comprising:
  • nanogel having a particle size of 80 nm or less and composed of a hydrophobized polysaccharide containing pullulan and cholesteryl groups.
  • a non-human mammal tumor model for identifying effective therapeutic agents for immune checkpoint inhibitor-resistant tumors wherein the tumor is murine fibrosarcoma CMS5a, and the non-human mammal is a mouse.
  • useful pharmaceutical compositions can be provided for treating tumors that do not express molecular targets of immune checkpoint inhibitors and are resistant to immune checkpoint inhibitors.
  • Enhancement of the anti-cancer activity of antigen-specific T cell infusions can be obtained by using an antigen-loaded nanogel that contains a hydrophobized polysaccharide-based nanogel as the delivery system, and a synthetic long chain peptide antigen or a recombinant protein antigen and an immune-enhancing agent as a pretreatment drug.
  • FIG. 1 shows data indicating the expression of PD-L1 and PD-1, and the numbers of tumor-infiltrating CD8+ T cells for various mouse tumors implanted subcutaneously and engrafted into BALB/c mice.
  • A is a photomicrograph showing the results of analyzing the expression of PD-L1 molecules in tumors locally after 7 days from being implanted
  • B is a graph showing the results of analyzing the PD-1 expression of CD3+ T cells localized in each tumor by flow cytometry
  • (C) is a graph showing the results of the analysis of the number of CD8+ T cells that infiltrated into each tumor.
  • FIG. 2 depicts graphs showing the results of examining the susceptibility to immune checkpoint inhibitors of various mouse tumors implanted subcutaneously and engrafted into BALB/c mice.
  • FIG. 3 depicts graphs showing the results of the therapeutic efficacy of antigen-specific T cell infusion on BALB/c mice that were subcutaneously transplanted with fibrosarcoma CMS5a tumors using a pretreatment drug that contains a long chain peptide antigen-loaded cholesteryl pullulan (CHP) nanogel and an immune-enhancing agent.
  • CHP cholesteryl pullulan
  • (A) is a graph showing that antigen-specific T cell infusion after subcutaneous administration of the long chain peptide antigen-loaded CHP nanogel and CpG oligo DNA can heal CMS5a tumors, and that incomplete Freund's adjuvant (IFA), instead of the nanogel as the delivery system, can not heal CMS5a tumors
  • (B) is a graph showing that antigen-specific T cell infusion after intravenous administration of the long chain peptide antigen-loaded CHP nanogel and CpG oligo DNA can heal CMS5a tumors, and that intravenous administration of the antigen-loaded nanogel of the present invention has the same effect as subcutaneous administration
  • (C) is a graph showing that antigen-specific T cell infusion after the administration of the long chain peptide antigen-loaded CHP nanogel and poly-IC RNA can heal CMS5a tumors, and that poly-IC RNA used as an immune-enhancing agent exhibits the same effect as CpG oligo DNA.
  • FIG. 4 depicts graphs showing the results of the therapeutic efficacy of antigen-specific T cell infusion on BALB/c mice that were subcutaneously transplanted with CMS5a tumors using a pretreatment drug that contains a long chain peptide antigen loaded CHP nanogel and an immune-enhancing agent.
  • (A) is a graph showing that antigen-specific T cell infusion after the administration of the long chain peptide antigen loaded CHP nanogel and CpG oligo DNA can heal CMS5a tumors, and that CpG oligo DNA without the long chain peptide antigen-loaded CHP nanogel cannot heal CMS5a tumors
  • (B) is a graph showing that antigen-specific T cell infusion after the administration of the long chain peptide antigen-loaded CHP nanogel and CpG oligo DNA can heal CMS5a tumors, and that the long chain peptide antigen-loaded CHP nanogel without CpG oligo DNA can not heal CMS5a tumors
  • (C) is a graph showing that antigen-specific T cell infusion after the administration of the long chain peptide antigen-loaded CHP nanogel and CpG oligo DNA can heal CMS5a tumors, and that the long chain peptide antigen-loaded CHP nanogel and CpG oligo DNA without the antigen-specific T cell infusion can
  • FIG. 5 depicts data showing the results of an uptake assay of CHP nanogels into tumor-associated immune cells when the CHP nanogel was administered intravenously to BALB/c mice in which CMS5a tumors were implanted subcutaneously.
  • FIG. 6 depicts data showing the results of analysis of antigen presenting activity of tumor-associated macrophages when the long chain antigen-loaded CHP nanogels and CpG oligo DNA were administered to BALB/c mice in which CMS5a tumors were implanted subcutaneously.
  • Pretreatment drugs of the present invention are characterized in that they comprise one or more immune-enhancing agents and a pharmaceutical composition, which contains a hydrophobized polysaccharide-based nanogel as a delivery system in which one or more synthetic long chain peptide antigens or recombinant protein antigens is (are) loaded, wherein the long chain peptide antigen(s) or the protein antigen(s) concurrently contains (contain) CD8+ cytotoxic T cell recognition epitope(s) and/or CD4+ helper T cell recognition epitope(s), which is (are) derived from a tumor-specific antigen protein or a tumor stroma-specific antigen.
  • a pharmaceutical composition which contains a hydrophobized polysaccharide-based nanogel as a delivery system in which one or more synthetic long chain peptide antigens or recombinant protein antigens is (are) loaded, wherein the long chain peptide antigen(s) or the protein antigen(s) concurrently contains (cont
  • the synthetic long chain peptide antigen preferably contains 23 to 120 amino acid residues and at least two T cell recognition epitopes.
  • the synthetic long chain peptide antigen preferably contains 23 to 80 amino acids and at least two T cell recognition epitopes.
  • the synthetic long chain peptide antigen preferably contains 23 to 60 amino acids and at least two T cell recognition epitopes.
  • the recombinant protein antigen preferably contains two or more T cell recognition epitopes and a tag sequence for purification if necessary, and is a full-length or partial-length antigen protein produced in E. coli. , insect cells or mammalian cells.
  • the CD8+ cytotoxic T cell recognition epitope(s) is (are) preferably (a) portion(s) of the amino acid sequence of a tumor-specific antigen protein or a tumor stroma-specific antigen protein.
  • the CD4+ helper T cell recognition epitope(s) is (are) preferably (a) portion(s) of the amino acid sequence of a tumor-specific antigen protein or a tumor stroma-specific antigen protein.
  • the tumor-specific antigen protein is preferably selected from the group consisting of the MAGE family, NY-ESO-1/LAGE, SAGE, XAGE, HER2, PRAME, Ras, 5T4, WT1, p53, MUC-1, hTERT, RHAMM, Survivin, EGFRvIII, HPV E6, MART-1, gp100, CEA, IDO, Brachyury, Mesothelin, PSA and PSMA.
  • the tumor stroma-specific antigen protein is preferably selected from the group consisting of FAP, the VEGFR family and TEM1.
  • the polysaccharide constituting the hydrophobized polysaccharide-based nanogel is preferably a pullulan or a mannan.
  • the hydrophobic group(s) of the hydrophobized polysaccharide-based nanogel is (are) preferably cholesterol.
  • the hydrophobized polysaccharide-based nanogel is preferably non-ionic.
  • the particle size of the hydrophobized polysaccharide-based nanogel is preferably 80 nm or less.
  • the immune-enhancing agent preferably includes a soluble TLR agonist, a soluble STING agonist or a soluble RLR agonist.
  • a soluble TLR agonist CpG oligo DNA or poly-IC RNA are exemplified.
  • soluble STING agonist cyclic dinucleotides, such as CdGMP, and xanthenone-derivatives, such as DMXAA, are exemplified.
  • soluble RLR agonist 5′-phosphorylated double-stranded RNA is exemplified.
  • the synthetic long chain peptide antigen or the recombinant protein antigen is characterized in that it comprises at least two or more T cell recognition epitopes contained in a tumor-specific antigen protein and/or in a tumor stroma-specific antigen protein.
  • T cell recognition epitopes are preferably those contained in a tumor-specific antigen protein or a tumor stroma-specific antigen protein.
  • MAGE family molecules such as MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A5, MAGE-A6, MAGE-A8, MAGE-A9, MAGE-A10, MAGE-A11, MAGE-Al2, MAGE-B1 and MAGE-B2, or T cell recognition epitopes contained in a tumor-specific antigen protein such as NY-ESO-1/LAGE molecule, SAGE, XAGE, HER2, PRAME, Ras, 5T4, WT1, p53, MUC-1, hTERT, RHAMM, Survivin, EGFRvIII, HPV E6, MART-1, gp100, CEA, IDO, Brachyury, Mesothelin, PSA and PSMA, or T cell recognition epitopes contained in tumor stroma-specific antigen proteins such as FAP, VEGFR family and TEM1.
  • MAGE-specific antigen protein such as NY-ESO-1/LAGE molecule, SAGE, XAGE, HER
  • T cell recognition epitopes there are CTL epitopes recognized by CD8+ cytotoxic T cells and Th epitopes recognized by CD4+ helper T cells.
  • the synthetic long chain peptide antigen or the recombinant protein antigen in the present invention preferably concurrently contains more than one each of the CTL epitopes and the Th epitopes.
  • a long chain peptide antigen containing (a) CTL epitope(s) and a long chain peptide antigen containing (a) Th epitope(s) can be used alone or in combination.
  • the hydrophobized polysaccharide used in the present invention can be prepared by known methods.
  • polysaccharides in the hydrophobized polysaccharides polymers in which sugar residues are glycosidically bound can be used without limitation.
  • the sugar residues constituting the polysaccharide may be derived, for example, from monosaccharides, such as glucose, mannose, galactose, and fucose, or from disaccharides or oligosaccharides.
  • the sugar residues may have 1,2-, 1,3-, 1,4- or 1,6-glycosidic bonds, and the bonds may be either a-type bonds or ⁇ -type bonds.
  • the polysaccharide may be linear or branched.
  • Glucose residues may be preferably used as the sugar residues; pullulan, dextran, amylose, amylopectin, or mannan of natural or synthetic origin may be used as the polysaccharide; preferably mannan or pullulan can be used.
  • the average molecular weight of the polysaccharide can range from 50,000 to 150,000.
  • alkyl or sterol residues which are introduced at a rate of 1 to 5 per 100 monosaccharides (less than 5% by weight) are preferably used, at a rate of 1 to 3 per 100 monosaccharides (less than 3% by weight) are more preferably used.
  • the alkyl groups or sterol residues are not limited; other residues can be used with good efficiency depending on the molecular weight or the isoelectric point of the encapsulated antigen.
  • sterol residue cholesterol, stigmasterol, beta-sitosterol, lanosterol and ergosterol residues are exemplified.
  • a cholesterol residue is used.
  • the alkyl group ones having 20 or less carbon atoms are preferably used; ones having 10 to 18 carbon atoms are more preferably used.
  • the alkyl group may be used in either a linear chain or a branched chain.
  • hydrophobized polysaccharide one in which 1-5 primary hydroxyl groups per 100 sugars are linked to a polysaccharide of the following formula (I):O—(CH 2 ) m CONH(CH 2 ) n NH—CO—O—R (I) (wherein R represents an alkyl group or a sterol residue; m represents 0 or 1; n represents any positive integer) is used preferably.
  • R represents an alkyl group or a sterol residue
  • m represents 0 or 1
  • n represents any positive integer
  • alkyl group or the sterol residue n is preferably 1 to 8.
  • hydrophobized polysaccharide one that is linked via a linker can be used.
  • hydrophobized polysaccharide a non-ionic one is preferably used.
  • the zeta potential of the hydrophobized polysaccharide-based nanogel particles in which the synthetic long chain peptide antigen or the recombinant protein antigen is loaded is preferably from ⁇ 2.0 mV to +2.0 mV under physiological conditions.
  • the particle size of the hydrophobized polysaccharide-based nanogel in which the synthetic long chain peptide antigen or the recombinant protein antigen is loaded is preferably 80 nm or less.
  • the pretreatment drug of the present invention that comprises an immune-enhancing agent and a pharmaceutical composition, which contains a hydrophobized polysaccharide-based nanogel as the delivery system in which a synthetic long chain peptide antigen or a recombinant protein antigen is loaded, may be administered in various ways.
  • Suitable non-oral administered routes such as intravenous, intraperitoneal, subcutaneous, intradermal, adipose tissue, mammary gland tissue, inhalation or intramuscular, or mucosal route in the form of nasal drops, are preferably used.
  • the pretreatment drug of the present invention is typically prepared as a kit that contains the antigen-loaded nanogel mixed with an immune-enhancing agent or the antigen-loaded nanogel and an immune-enhancing agent separately.
  • the agent may be prepared in a suitable dosage form for subcutaneous, intravenous, or intramuscular administration.
  • the dose of the antigen-loaded nanogel necessary to induce the desired immunity can be appropriately determined.
  • the usual dose can be used in an amount of about 0.1 mg/administration to 10 mg/administration, as the synthetic long chain peptide antigen or the recombinant protein antigen.
  • the number of times of administration is suitably 2 to 20 times.
  • the administration interval between the pretreatment drug and the antigen-specific T cell infusion is selected between 1 day to 2 weeks.
  • the present invention provides a pretreatment drug of a therapeutic agent, which contains a cell population that includes antigen-specific T cells as the active ingredient.
  • the cell population suitable for the treatment of a patient is administered, for example, by intravenous injection or infusion, intraarterially, subcutaneously, or intraperitoneally.
  • the cell population can be prepared as a drip infusion or injection according to methods known in the pharmaceutical field by mixing excipients, stabilizers, etc. with a known organic or inorganic carrier that is suited for non-oral administration.
  • the content, the dose and other conditions of the cell population may be appropriately determined according to known immunotherapy.
  • the content of the cell population in the pharmaceutical is preferably 1 ⁇ 10 3 to 1 ⁇ 10 11 cells/mL, more preferably 1 ⁇ 10 4 to 1 ⁇ 10 10 cells/mL, more preferably 1 ⁇ 10 5 to 2 ⁇ 10 9 cells/mL.
  • the dosage of the therapeutic agent containing the cell population as the active ingredient is preferably 1 ⁇ 10 6 to 1 ⁇ 10 12 cells/day per adult, more preferably 1 ⁇ 10 7 to 5 ⁇ 10 11 cells/day per adult, more preferably 1 ⁇ 10 8 to 2 ⁇ 10 11 cells/day per adult.
  • a step of introducing a foreign gene into the cell population can be included the manufacturing method of the cell population.
  • a foreign gene means a gene that is artificially introduced into the cell population containing the target T cells, and also encompasses genes from the same species of the target cells.
  • the means for introducing a foreign gene is not limited, and can be appropriately selected and used according to known gene introduction methods. Gene transfer can be carried out with a viral vector or without a viral vector. Many papers have been previously reported concerning these methods.
  • viral vector without limitation, known viral vectors used for gene transfer, for example, such as retroviral vectors, lentiviral vectors, adenoviral vectors, adeno-associated virus vectors, simian viral vectors, vaccinia virus vectors, or Sendai viral vectors or the like, can be used.
  • Retroviral vector or lentiviral vector which can stably incorporate a foreign gene into a chromosomal DNA in targeted cells, preferably can be used.
  • those that lack replication ability preferably can be used so that they can not self-replicate in an infected cell.
  • RetroNectin® RetroNectin®
  • retroNectin® RetroNectin®
  • methods using carriers such as liposomes or ligand-polylysine, calcium phosphate method, electroporation methods, or particle gun methods and the like can be used.
  • a foreign gene integrated in plasmid DNA, in a linear DNA or in an RNA is introduced.
  • the foreign gene that is introduced is not particularly limited; any foreign genes can be used (for example, enzymes, cytokines, chemokines, or antigen receptors such as T-cell receptors (TCR) or chimeric antigen receptors (CAR), genes encoding proteins such as a receptor of a co-stimulant or ligand, antisense nucleic acids, siRNA, miRNA, ribozymes, and genes encoding aptamers).
  • Foreign genes for example, can be used by inserting into a vector or plasmid so as to be expressed under the control of a suitable promoter. Regulatory sequences such as enhancer sequences or terminator sequences can be incorporated within the vector.
  • a target of a therapeutic agent using an antigen-loaded nanogel, an immune-enhancing agents, and an antigen-specific T cell infusion is a human who has a tumor that is resistant to immune checkpoint inhibitors.
  • Tumors types such as prostate cancer, colon cancer, melanoma, head and neck cancer, esophageal cancer, stomach cancer, colorectal cancer, liver cancer, gallbladder-bile duct cancer, pancreatic cancer, lung cancer, breast cancer, ovarian cancer, bladder cancer, kidney cancer, testicular cancer, bone and soft tissue sarcoma, malignant lymphoma, leukemia, cervical cancer, skin cancer, brain tumors and the like, are exemplified without limitation.
  • Anti-mouse CD16/CD32 antibody (clone 93), PE-labeled anti-mouse PD-L1 antibody (clone 9G2), APC-Cy7-labeled anti-CD45 antibody (clone 30-F11), and PE-Cy7-labeled anti-PD-1 antibody (clone 29F.1A12) were purchased from Biolegend.
  • V450-labeled anti-CD8 antibody (clone 53-6.7) was purchased from eBioscience.
  • Fetal bovine serum (FBS) was purchased from Bio-West.
  • RPMI1640 medium (containing 2-mercaptoethanol) was purchased from the Cell Science Institute.
  • Erythrocyte hemolysis solution (0.15 M NH 4 Cl/10 mM KHCO 3 /0.1 mM EDTA.Na 2 pH 7.2) was prepared at Mie University.
  • Mouse colon cancer CT26 cell line (CRL-2638) was purchased from ATCC and was used as subcultured at Mie University.
  • Mouse fibrosarcoma CMS7 cell line and murine fibrosarcoma CMS5a cell line were obtained from Memorial Sloan-Kettering Cancer Institute and were used as subcultured at Mie University.
  • Human NY-ESO-1 antigen gene was obtained from Memorial Sloan-Kettering Cancer Institute.
  • CMS5a-NY cell line which is a CMS5a cell line stably transfected with human NY-ESO-1 antigen gene, was produced at Mie University, and was used as subcultured.
  • Female BALB/c mice from 6-weeks-old to 12-weeks-old were purchased from Japan SLC and housed at the Mie University School of Medicine Animal Center. Protocols for animal experiments were approved by the ethics committee of the Mie University School of Medicine.
  • mice fibrosarcoma CMS7 cell line, mouse fibrosarcoma CMS5a cell line, and CMS5a-NY cell line were cultured in 10% FBS-containing RPMI1640 medium using T75 culture flasks (Corning). Each cell line was detached from the flasks using 0.5% trypsin-containing phosphate-buffered saline (PBS), and suspended in 10% FBS-containing RPMI1640 medium. The suspensions were centrifuged (400 ⁇ g, 5 min, 4° C.) to remove the supernatants. The cells were washed twice with RPMI1640 medium and suspended in RPMI1640 medium at a concentration of 1 ⁇ 10 6 /100 ⁇ L. The suspensions were subcutaneously implanted into the backs of the BALB/c mice at a dose of 100 ⁇ L/individual (3 mice per group).
  • Tumors were stained immunohistochemically in the following manner. Tumors embedded in O.C.T. compound (Sakura Finetech) were frozen and sliced into 3 p.m thicknesses. The sliced tumor sections were air dried for 2 hours. Dried tumor sections were fixed with ice cold acetone for 15 minutes and used for immunostaining. After the tumor sections were washed 3 times with PBS, they were immersed in blocking solution (1% bovine serum albumin (BSA) and 5% Blocking One Histo (Nacalai Tesque) containing PBS) at 4° C.
  • BSA bovine serum albumin
  • Blocking One Histo Nacalai Tesque
  • Anti-mouse CD16/CD32 antibody was diluted in blocking solution at a concentration of 1 ⁇ g/mL.
  • the tumor sections were treated with the antibody solution for 30 minutes at room temperature in a humidified box to block Fc ⁇ receptors.
  • the tumor sections were stained with PE-labeled anti-mouse PD-L1 antibody diluted at a concentration of 1 ⁇ g/mL in blocking solution for 1 hour at room temperature in a humidified box.
  • After the tumor sections were washed three times with 0.02% Tween20-containing PBS, they were immersed in Prolong Gold antifade reagent with DAPI (Life Technologies).
  • the tumor sections were observed with a fluorescent microscope BX53F (Olympus) or confocal laser scanning microscope LSM780 (Carl Zeiss). The microscopic images were processed using Photoshop Element (Adobe Systems).
  • Each cell line was implanted subcutaneously; after 1 week, immune cells that infiltrated the tumors were separated in the following manner. Tumors were isolated from the mice, crushed using gentleMACS (Miltenyi), and suspended in RPMI1640 medium. At this time, separated cells from 3 mice in a group were pooled. Collagenase D (final concentration 2 mg/mL, Roche) was added to the suspended cells, reacted for 30 minutes at 37° C., and the cells were crushed again using gentleMACS.
  • the cells were filtered with a filter (22- ⁇ m pore size, BD Biosciences) and centrifuged (400 ⁇ g, 5 min, 4° C.); the supernatant was removed and 2 mL of erythrocyte hemolysis solution was added to the cells. After one minute, 18 mL of RPMI1640 medium was added, and the cells were centrifuged (400 ⁇ g, 5 min, 4° C.). After the supernatant was removed, the cells were suspended in RPMI1640 medium. After counting the number of cells, they were suspended in staining buffer (0.5% BSA-containing PBS) to yield a cell concentration of 3 ⁇ 10 7 cells/mL.
  • staining buffer (0.5% BSA-containing PBS
  • the cell suspensions were transferred to a 96-well V-bottom microplate (Nunc). The microplate was centrifuged (2000 rpm, 1 min, 4° C.). After removing the supernatant, the cells were suspended in 50 ⁇ L of staining buffer per well. APC-Cy7-labeled anti-mouse CD45 antibody, V450-labeled anti-mouse CD8 antibody, and PE-Cy7-labeled anti-mouse PD-1 antibody were added to the cells at the recommended usage concentrations of the manufacturer of each antibody. After mixing gently, they were allowed to stand in the dark for 15 minutes at 4° C.
  • the cells were washed twice with 200 ⁇ L of staining buffer, suspended in 200 ⁇ L of staining buffer, and transferred to round-bottomed polystyrene tubes (BD Biosciences). The cells were analyzed using a flow cytometer FACS Canto II (BD Biosciences) and data analysis software FlowJo (Tree Star). The frequency of PD-1 expression was determined as expression frequencies (%) in the cell populations of CD45+ and CD8+. The frequency of CD8+ T cells was determined as the frequency (%) of CD8+ cells in the CD45+ cell population.
  • Immune checkpoint inhibitor-resistant human tumors exhibit the characteristics in that there is an expression-deficiency of immune checkpoint molecules and tumor-infiltration of CD8+ T cells is not observed (Non-patent Document 5).
  • Non-patent Document 5 To search for a mouse tumor exhibiting the same characteristics, after various mouse cancer cell lines were implanted subcutaneously in BALB/c mice, tumors were harvested; expression of immune checkpoint molecules PD-L1 and PD-1 and the number of infiltrating CD+ T cells were measured.
  • FIG. 1(A) shows the results of the expression of PD-L1 molecules in CT26 tumors, CMS7 tumors, CMS5a-NY tumors and CMS5a tumors analyzed by immunostaining.
  • FIG. 1(B) shows the results of the expression frequency of PD-1 in CD3+ T cells in tumor sites of tumors according to flow cytometry. Compared to the other tumors, the percentage of PD-1 expressing CD3+ T cells in CMS5a tumors was the lowest.
  • FIG. 1(C) shows the frequency of CD8+ T cells that infiltrated into the tumor site of each tumor. Compared to other tumors, in CMS5a tumors the frequency of tumor-site-infiltrating CD8+ T cells was remarkably low. From these results, mouse tumor fibrosarcoma formed by implantation of the CMS5a cell line subcutaneously in mice was found to exhibit the same characteristics as immune checkpoint inhibitor-resistant human tumors.
  • a hybridoma that expresses anti-mouse CTLA-4 antibody (clone 9D9) was obtained from Dr. James P. Allison at the MD Anderson Cancer Center, and antibody was prepared at Mie University.
  • a hybridoma that expresses anti-mouse GITR antibody (clone DTA-1) was obtained from Dr. Shimon Sakaguchi at Osaka University, and antibody was prepared at Mie University.
  • Anti-mouse-PD-1 antibody (clone RMP1-14) was obtained from Dr. Hideo Yagita at Juntendo University.
  • Fetal bovine serum (FBS) was purchased from Bio-West.
  • RPMI1640 medium (containing 2-mercaptoethanol) was purchased from the Cell Science Institute.
  • Mouse colon cancer CT26 cell line (CRL-2638) was purchased from ATCC and was used as subcultured at Mie University.
  • Mouse fibrosarcoma CMS7 cell line and murine fibrosarcoma CMS5a cell line were obtained from Memorial Sloan-Kettering Cancer Institute and were used as subcultured at Mie University.
  • Human NY-ESO-1 antigen gene was obtained from Memorial Sloan-Kettering Cancer Institute.
  • CMS5a-NY cell line which is a CMS5a cell line stably transfected with human NY-ESO-1 antigen, was produced at Mie University, and was used as subcultured.
  • Female BALB/c mice from 6-weeks-old to 12-weeks-old were purchased from Japan SLC and housed at the Mie University School of Medicine Animal Center. Protocols for animal experiments were approved by the ethics committee of the Mie University School of Medicine.
  • the CT26 cell line, CMS7 cell line, CMS5a cell line, and CMS5a-NY cell line were cultured in 10% FBS-containing RPMI1640 medium using T75 culture flasks (Corning). Each cell line was detached from the flasks using 0.5% trypsin-containing phosphate buffer saline (PBS), and suspended in 10% FBS-containing RPMI1640 medium. The suspensions were centrifuged (400 ⁇ g, 5 min, 4° C.) to remove the supernatants. The cells were washed twice with RPMI1640 medium and suspended in RPMI1640 medium at a concentration of 1 ⁇ 10 6 /100 ⁇ L.
  • PBS trypsin-containing phosphate buffer saline
  • the suspensions were subcutaneously implanted in the backs of the BALB/c mice at a dose of 100 ⁇ L/individual (4 mice per group).
  • anti-mouse GITR antibody diluted in PBS (100 ⁇ g) were intraperitoneally administered as immune checkpoint inhibitors simultaneously at 7, 9 and 11 days after the tumor implantation.
  • the length and breadth of the tumors were measured after the tumor transplantation over time, and the tumor volumes were calculated according to the formula: (longer diameter ⁇ shorter diameter ⁇ shorter diameter ⁇ 0.5).
  • Statistical analysis was performed by non-parametric test using Microsoft Excel (Microsoft).
  • CMS5a tumors were proved to exhibit strong resistance to immune checkpoint inhibitors. Together with the results of Example 1, CMS5a tumors were considered to be a good model of immune checkpoint inhibitor-resistant human tumors. It became clear that effective treatments for immune checkpoint inhibitor-resistant human tumors were to be examined by using CMS5a tumors as the evaluation system.
  • CHP Cholesteryl pullulan
  • IFA incomplete Freund's adjuvant
  • F5506 Long chain peptide antigen-loaded CHP nanogel was prepared as follows.
  • MEN peptide: SNPARYEFLYYYYYYQYIHSANVLYYYYYYRGPESRLL (SEQ ID NO: 1) and p121 peptide: NDHIAYFLYQILRGLQYIHSANVLHRDLKPSNLLLNT (SEQ ID NO: 2)) were chemically synthesized by Bio-Synthesis and were dissolved in dimethyl sulfoxide (abbreviation DMSO, Nacalai Tesque) at a concentration of 10 mg/mL.
  • CHP was dissolved in phosphate-buffered saline (PBS) containing 6 M urea (Nacalai Tesque) at a concentration of 10 mg/mL.
  • PBS phosphate-buffered saline
  • dialysis was performed using PBS as the external dialysis solution in a volume ratio of 100 times or more for 2 hours to overnight at 4° C.
  • the long chain peptide antigen:IFA mixture was prepared as follows.
  • the long chain peptide antigen was dissolved at a concentration of 60 ⁇ g/125 ⁇ L in PBS containing 25% DMSO and collected into a syringe. Separately, 125 ⁇ L of IFA was drawn into another syringe. After both syringes were connected by a three-way stopcock, suctioning and discharging by the syringes were repeated. After mixing well, the solution was used for administration.
  • Fetal bovine serum (FBS) was purchased from Bio-West.
  • RPMI1640 medium (containing 2-mercaptoethanol) was purchased from the Cell Science Institute.
  • Mouse fibrosarcoma CMS5a cell line was obtained from Memorial Sloan-Kettering Cancer Institute, and was used as subcultured at Mie University.
  • Mouse fibrosarcoma CMS5a cell line expresses mutated ERK2 protein.
  • a peptide containing the mutation site of the mutated ERK2 protein (QYIHSANVL: SEQ ID NO: 3, the underline indicates the mutation) is recognized by CD8+ cytotoxic T cells of BALB/c mice.
  • a T cell receptor (TCR) that recognizes the mutant peptide was isolated, and TCR gene-introduced mice (DUC18 mice) have been produced.
  • the long chain peptide antigens used in the example (MEN peptide and p121 peptide) contain a CD8+ cytotoxic T-cell recognition epitope sequence of the mutated ERK2 (QYIHSANVL: SEQ ID NO. 3).
  • mice from 6-weeks-old to 12-weeks-old were purchased from Japan SLC.
  • DUC18 mice were obtained from the University of Washington, and were used as bred at Mie University. The mice were bred at the Mie University School of Medicine Animal Center. Protocols for animal experiments were approved by the ethics committee of the Mie University School of Medicine.
  • Mouse fibrosarcoma CMS5a cell line was cultured in 10% FBS-containing RPMI1640 medium using a T75 culture flask (Corning). The cell line was detached from the flask using 0.5% trypsin-containing PBS and suspended in 10% FBS-containing RPMI1640 medium. The suspension was centrifuged (400 ⁇ g, 5 min, 4° C.) to remove the supernatant. The cells were washed twice with RPMI1640 medium and suspended in RPMI1640 medium at a concentration of 1 ⁇ 10 6 /100 ⁇ L. The suspension was subcutaneously implanted in both sides of the backs of BALB/c mouse at a dose of 100 ⁇ L/individual (4 mice per group).
  • the long chain peptide antigen-loaded CHP nanogel or the long chain peptide antigen:IFA mixture was administered subcutaneously into the backs or tail veins of the mice together with 50 ⁇ g of CpG oligo DNA1668 (Gene Design) or 50 ⁇ g of Poly-ICLC RNA (Oncovir) in PBS as the immune-enhancing agent.
  • the p121 peptide was used as the long chain peptide antigen.
  • the MEN peptide was used.
  • CD8+ T cells in the spleen of mutated ERK2-specific TCR transgenic mice were isolated using a CD8a+ T Cell Isolation Kit (Miltenyi). Isolated CD8+ T cells were suspended in RPMI1640 medium at a concentration of 2 ⁇ 10 6 cells/200 ⁇ L. After 8 days and 12 days from tumor implantation, isolated CD8+ T cells were infused from within the tail vein as antigen-specific T cells for the treatment. Statistical analysis was performed by non-parametric test using Microsoft Excel (Microsoft).
  • a pretreatment drug that omitted the long chain peptide antigen loaded CHP nanogel was found to be not effective.
  • a pretreatment drug that omitted the immune-enhancing agent CpG oligo DNA
  • the pretreatment drug of the antigen-specific T cell infusion must contain a long chain peptide antigen-loaded CHP nanogel and an immune-enhancing agent.
  • administration of only the pretreatment drug was found to be not effective.
  • the pretreatment drug of the invention when combined with the antigen-specific T cell infusion, was found to treat immune checkpoint inhibitor-resistant tumors.
  • Rhodamine-labeled CHP nanogel was obtained from Dr. Kazunari Akiyoshi at Kyoto University.
  • APC-Cy7-labeled anti-mouse CD45 antibody (clone 30-F11), FITC-labeled anti-mouse CD8 antibody (clone 53-6.7), PE-labeled anti-mouse CD11b antibody (clone M1/70), Pacific blue-labeled anti-mouse F4/80 antibody (clone BM8) and PE-Cy7-labeled anti-mouse CD11c antibody (clone N418) were purchased from BioLegend.
  • PerCP-Cy5.5-labeled anti-mouse CD4 antibody (clone RM4-5) was purchased from BD Biosciences.
  • APC-labeled anti-mouse B220 antibody (clone RA3-6B2) was purchased from eBioscience. Fetal bovine serum (FBS) was purchased from Bio-West. RPMI1640 medium (containing 2-mercaptoethanol) was purchased from the Cell Science Institute. Erythrocyte hemolysis solution (0.15 M NH 4 Cl/10 mM KHCO 3 /0.1 mM EDTA.Na 2 pH 7.2) was prepared at Mie University. Mouse fibrosarcoma CMS5a cell line was obtained from Memorial Sloan-Kettering Cancer Institute and was used as subcultured at Mie University. Female BALB/c mice from 6-weeks-old to 12-weeks-old were purchased from Japan SLC and housed at the Mie University School of Medicine Animal Center. Protocols for animal experiments were approved by the ethics committee of the Mie University School of Medicine.
  • the mouse fibrosarcoma CMS5a cell line was cultured in 10% FBS-containing RPMI1640 medium using a T75 culture flask (Corning). The cell line was detached from the flask using 0.5% trypsin-containing phosphate buffer saline (PBS), and suspended in 10% FBS-containing RPMI1640 medium. The suspension was centrifuged (400 ⁇ g, 5 min, 4° C.) to remove the supernatant. The cells were washed twice with RPMI1640 medium.
  • PBS trypsin-containing phosphate buffer saline
  • the cells were suspended in RPMI1640 medium at a concentration of 1 ⁇ 10 6 /100 ⁇ L; the cells were implanted subcutaneously into the backs of BALB/c mice at a dose of 100 ⁇ L/individual (4 per group).
  • 1 mg of Rhodamine-labeled CHP nanogel (10 mg/mL PBS) was subcutaneously administered to the backs or to the tail vein.
  • tumor-infiltrating immune cells were separated by the following method. Tumors were isolated from the mice, crushed using gentleMACS (Miltenyi) and suspended in RPMI1640 medium. Separated cells from 4 mice in a group were pooled.
  • Collagenase D (final concentration 2 mg/ml, Roche) was added to suspended cells, reacted for 30 min at 37° C., and the cells were crushed again using gentleMACS.
  • the cells were filtered with a filter (22- ⁇ m pore size, BD Biosciences) and centrifuged (400 ⁇ g, 5 min, 4° C.); the supernatant was removed and 2 mL of erythrocyte hemolysis solution was added to the cells. After one minute, 18 mL of RPMI1640 medium was added, and the cells were centrifuged (400 ⁇ g, 5 min, 4° C.). After the supernatant was removed, the cells were suspended in RPMI1640 medium.
  • lymph nodes were collected. In the case of subcutaneous administration, lymph nodes of the administration site (the inguinal lymph nodes) were collected; in the case of intravenous administration, tumor draining lymph nodes (inguinal lymph nodes) were collected.
  • RPMI1640 medium After grinding the lymph nodes using a glass slide, released cells were suspended in RPMI1640 medium. At this time, cells from 4 mice in a group were pooled. The suspension was centrifuged (400 ⁇ g, 5 min, 4° C.) to remove the supernatant, and the cells were treated for 1 min by adding 2 mL of erythrocyte hemolysis solution. 18 mL of RPMI1640 medium was added, and the cells were centrifuged (400 ⁇ g, 5 min, 4° C.). After removing the supernatant, the cells were suspended in RPMI1640 medium. The cell suspension was centrifuged (400 ⁇ g, 5 min, 4° C.) and the supernatant was removed.
  • the cells were washed twice with 2% FBS-containing PBS, and suspended.
  • the cells were washed twice with 200 ⁇ L of staining buffer, re-suspended in 200 ⁇ L of staining buffer, and transferred to round-bottomed polystyrene tubes (BD Biosciences). The cells were analyzed using a flow cytometer FACS Canto II (BD Biosciences) and data analysis software FlowJo (Tree Star).
  • T cells were detected as CD45+ and CD4+, or CD45+ and CD8+; B cells were detected as CD45+ and B220+, macrophages were detected as CD45+ and CD11b+and CD11c+and F4/80+.
  • the Rhodamine+cells in each of the immune cells were detected as CHP nanogel uptake cells.
  • the pretreatment drug of the invention showed similar therapeutic effects against the immune checkpoint inhibitor-resistant CMS5a tumors in both subcutaneous and intravenous administration.
  • the uptake of CHP nanogel into immune cells was measured in lymph nodes and tumor sites.
  • subcutaneously administered CHP nanogel was taken up well into macrophages of administered regional lymph nodes.
  • intravenously administered CHP nanogel was taken up well into tumor-associated macrophages.
  • Fetal bovine serum was purchased from Bio-West.
  • RPMI1640 medium (containing 2-mercaptoethanol) was purchased from the Cell Science Institute.
  • Erythrocyte hemolysis solution (0.15 M NH 4 Cl/10 mM KHCO 3 /0.1 mM EDTA.Na 2 pH 7.2) was prepared at Mie University.
  • Mouse fibrosarcoma CMS5a cell line was obtained from Memorial Sloan-Kettering Cancer Institute, and was used as subcultured at Mie University.
  • Female BALB/c mice from 6-weeks-old to 12-weeks-old were purchased from Japan SLC.
  • Mutated ERK2-specific TCR transgenic mice (DUC18 mice) were obtained from the University of Washington, and were used as bred at Mie University. The mice were bred at the Mie University School of Medicine Animal Center. Protocols for animal experiments were approved by the ethics committee of the Mie University School of Medicine.
  • the mouse fibrosarcoma CMS5a cell line was cultured in 10% FBS-containing RPMI1640 medium using a T75 culture flask (Corning). The cell line was detached from the flask using 0.5% trypsin-containing PBS, and suspended in 10% FBS-containing RPMI1640 medium. The suspension was centrifuged (400 ⁇ g, 5 min, 4° C.) to remove the supernatant. The cells were washed twice with RPMI1640 medium and suspended in RPMI1640 medium at a concentration of 1 ⁇ 10 6 /100 ⁇ L. The suspension was subcutaneously implanted in both sides of the backs of BALB/c mouse at a dose of 100 ⁇ L/individual (5 mice per group).
  • a long chain peptide antigen-loaded CHP nanogel 60 ⁇ g as MEN peptide, dissolved in PBS
  • CpG oligo DNA1668 50 ⁇ g, dissolved into PBS, Gene Design
  • cells from 5 mice in a group were pooled.
  • the suspensions were centrifuged (400 ⁇ g, 5 min, 4° C.) to remove supernatant, and the cells were treated for 1 min by adding 2 mL of erythrocyte hemolysis solution. 18 mL of RPMI1640 medium was added, and the cells were centrifuged (400 ⁇ g, 5 min, 4° C.). After removing the supernatant, the cells were suspended in RPMI1640 medium. After the spleen and inguinal lymph nodes were triturated with a glass slide, released cells were collected in RPMI1640 medium. At this time, cells from 5 mice in a group were pooled.
  • the suspensions were centrifuged (400 ⁇ g, 5 min, 4° C.) to remove the supernatant, and the cells were treated for 1 minute by adding 2 mL of erythrocyte hemolysis solution. 18 mL of RPMI1640 medium was added, and the cells were centrifuged (400 ⁇ g, 5 min, 4° C.). After removing the supernatant, the cells were suspended in RPMI1640 medium (it was called “the primary cell suspension”). The primary cell suspension prepared from each tissue was centrifuged (400 ⁇ g, 5 min, 4° C.) and the supernatant was removed. After the cells were washed twice with 2% FBS-containing PBS, they were suspended in 2% FBS-containing PBS.
  • the suspension was called “the secondary cell suspension”.
  • CD11b+ cells were isolated from the secondary cell suspension using CD11b microbeads (Miltenyi). These cells were used as antigen presenting cells from each tissue.
  • CD8+ T cells were isolated from the spleen of DUC18 mice in the same manner as in Example 3. Then, responder T cells were prepared by labeling with the fluorescent dye CFSE (Thermo Fisher Science). 2.5 ⁇ 10 5 cells of antigen presenting cells and 2 ⁇ 10 5 cells of responder T cells per well were added to a 96-well V-bottom microplate (Nunc), and co-cultured for 72 hours in 10% FBS-containing RPMI1640 medium.
  • the fluorescence of CFSE is attenuated with the cell division.
  • the change of the fluorescence was measured using a flow cytometer FACS Canto II (BD Biosciences) and data analysis software FlowJo (Tree Star). The percentage of responder T cells that divided more than once was calculated, and the antigen presenting ability of antigen-presenting cells from each tissue was evaluated.
  • Example 4 it was revealed that intravenously administered CHP nanogel was taken up selectively by tumor-associated macrophages. It was considered that the long chain peptide antigen-loaded CHP nanogels administered intravenously were taken up into tumor-associated macrophages, and the antigen was presented to the infused antigen-specific T cells to enhance the activity of the antigen-specific T cells. The following experiments were performed to confirm the antigen-presenting activity of tumor-associated macrophages.
  • CD11b+ macrophages in tumors or various tissues were isolated from BALB/c mice in which CMS5a tumors had been implanted subcutaneously; CHP nanogel, which was loaded with a long chain peptide antigen containing the CD8+ T cell recognition epitope of mutated ERK2, and CpG oligoDNA were intravenously administered.
  • the CD11b+ macrophages as antigen-presenting cells were co-cultured in vitro with the CD8+ T cells from mutated ERK2-specific TCR transgenic mice.
  • the CD8+ T cells from mutated ERK2-specific TCR transgenic mice are activated and proliferate.
  • the fluorescence was measured by CFSE dilution test using flow cytometry to estimate the T cell proliferation and was used as an indicator of antigen presentation.
  • the mechanism has been thought to be the same in non-human mammals, including monkey, mouse, rat, pig, cattle, and dog.
  • the composition of the invention is believed to have the same effect on humans, monkeys, mice, rats, pigs, cattle, dogs, etc.
  • the enhancement of the anti-cancer activity of antigen-specific T cell infusion was derived by a synthetic long chain peptide antigen or recombinant protein antigen loaded-nanogel using a hydrophobized polysaccharide-based nanogel as the delivery system and an immunological enhancer, serving as a pretreatment drug.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
US16/077,238 2016-02-08 2017-02-08 Pretreatment drug for t cell infusion therapy for immune-checkpoint inhibitor-resistant tumor Abandoned US20190111078A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016-022081 2016-02-08
JP2016022081 2016-02-08
PCT/JP2017/004552 WO2017138557A1 (ja) 2016-02-08 2017-02-08 免疫チェックポイント阻害剤抵抗性腫瘍に対するｔ細胞輸注療法の前処置薬

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2017/004552 A-371-Of-International WO2017138557A1 (ja) 2016-02-08 2017-02-08 免疫チェックポイント阻害剤抵抗性腫瘍に対するｔ細胞輸注療法の前処置薬

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/071,010 Division US20230201263A1 (en) 2016-02-08 2022-11-29 Pretreatment drug for t cell infusion therapy for immune-checkpoint inhibitor-resistant tumor

Publications (1)

Publication Number Publication Date
US20190111078A1 true US20190111078A1 (en) 2019-04-18

Family

ID=59563163

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/077,238 Abandoned US20190111078A1 (en) 2016-02-08 2017-02-08 Pretreatment drug for t cell infusion therapy for immune-checkpoint inhibitor-resistant tumor
US18/071,010 Pending US20230201263A1 (en) 2016-02-08 2022-11-29 Pretreatment drug for t cell infusion therapy for immune-checkpoint inhibitor-resistant tumor

Family Applications After (1)

Application Number Title Priority Date Filing Date
US18/071,010 Pending US20230201263A1 (en) 2016-02-08 2022-11-29 Pretreatment drug for t cell infusion therapy for immune-checkpoint inhibitor-resistant tumor

Country Status (8)

Country Link
US (2) US20190111078A1 (zh)
EP (1) EP3415159B1 (zh)
JP (2) JP6898539B2 (zh)
KR (1) KR20180105232A (zh)
CN (1) CN108697777A (zh)
AU (1) AU2017216653B2 (zh)
CA (1) CA3014027A1 (zh)
WO (1) WO2017138557A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11497768B2 (en) 2017-06-05 2022-11-15 Mie University Antigen-binding protein that recognizes MAGE-A4-derived peptide
US11940444B2 (en) 2013-11-08 2024-03-26 Mcmaster University Method of stabilizing molecules without refrigeration using water soluble polymers and applications thereof in performing chemical reactions

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108578706B (zh) * 2018-05-04 2020-07-07 国家纳米科学中心 一种CpG药物及其制备方法和应用
US20210299187A1 (en) * 2018-06-25 2021-09-30 Immodulon Therapeutics Limited Cancer therapy
JP2022539831A (ja) * 2019-07-11 2022-09-13 グッド ティー セルズ、 インコーポレイテッド 免疫チェックポイント阻害剤抵抗性癌の予防、改善または治療用組成物
CN111184684B (zh) * 2020-02-08 2022-08-30 苏州大学 一种红细胞凝胶递释系统及其制备方法与应用
KR20240016309A (ko) * 2021-05-31 2024-02-06 고쿠리츠다이가쿠호진 미에다이가쿠 의약 조성물
TW202320854A (zh) * 2021-08-17 2023-06-01 日商聯合免疫股份有限公司 癌治療劑
CN115969971B (zh) * 2022-11-24 2023-08-18 珠海恩科生物科技有限公司 组合物在制备治疗肿瘤的药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014514927A (ja) * 2011-04-13 2014-06-26 イミュニカム・エイビイ 抗原特異的ｔ細胞の増殖のための方法
JP6041314B2 (ja) * 2011-08-31 2016-12-07 国立大学法人三重大学 がん治療用ワクチン製剤
WO2015050158A1 (ja) * 2013-10-01 2015-04-09 国立大学法人三重大学 抗原提示を促進するエピトープ間配列を含むｔ細胞誘導ワクチン

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11940444B2 (en) 2013-11-08 2024-03-26 Mcmaster University Method of stabilizing molecules without refrigeration using water soluble polymers and applications thereof in performing chemical reactions
US11497768B2 (en) 2017-06-05 2022-11-15 Mie University Antigen-binding protein that recognizes MAGE-A4-derived peptide

Also Published As

Publication number Publication date
CA3014027A1 (en) 2017-08-17
AU2017216653A1 (en) 2018-08-23
EP3415159B1 (en) 2023-12-13
JP2021113215A (ja) 2021-08-05
WO2017138557A1 (ja) 2017-08-17
CN108697777A (zh) 2018-10-23
JPWO2017138557A1 (ja) 2019-02-28
JP6898539B2 (ja) 2021-07-07
US20230201263A1 (en) 2023-06-29
KR20180105232A (ko) 2018-09-27
EP3415159A1 (en) 2018-12-19
AU2017216653B2 (en) 2021-12-23
EP3415159A4 (en) 2019-12-11

Similar Documents

Publication Publication Date Title
US20230201263A1 (en) Pretreatment drug for t cell infusion therapy for immune-checkpoint inhibitor-resistant tumor
JP6858128B2 (ja) 癌治療のための免疫療法とサイトカイン制御療法との組み合わせ
WO2021053667A2 (en) Combination cancer therapy and cytokine control therapy for cancer treatment
JP2021514665A (ja) がんおよび感染症を処置するための治療用細胞系および方法
CN106999552B (zh) 治疗癌症的方法和组合物
JP2019532648A (ja) がんの治療のための膜係留ｉｌ−１２を発現しているｔ細胞
JP2021121198A (ja) 免疫機能制御因子を発現する免疫担当細胞
JP2022527297A (ja) Ｔｎ－ＭＵＣ１キメラ抗原受容体（ＣＡＲ）Ｔ細胞療法
JP2017524348A (ja) 養子細胞移入のためのｐｔｐｎ２阻害を用いた白血球の産生方法
US20220378826A1 (en) Tumour infiltrating lymphocyte therapy and uses thereof
WO2021108455A1 (en) Methods for activation and expansion of tumor infiltrating lymphocytes
AU2020350221A1 (en) Combination cancer therapy and cytokine control therapy for cancer treatment
JP2021536247A (ja) 併用療法用ｄｎａワクチンを標的とするネオアンチゲン
WO2017221850A1 (ja) Ｔ細胞機能向上のためのアダプター分子
Nikoo et al. Potential of chimeric antigen receptor (CAR)‐redirected immune cells in breast cancer therapies: recent advances
CN110996974A (zh) 增加免疫应答的材料和方法
EP4349366A1 (en) Pharmaceutical composition
WO2023081733A1 (en) Compositions and methods of treatment for cancers
Wang Sialoglycan–Siglec axis in the modulation of dendritic cells functions
WO2024044771A2 (en) Pegylation of car t cell therapeutics
WO2023244499A2 (en) Improved glycan-dependent immunotherapeutic bi-specific fusion proteins and chimeric antigen receptors
TW202304481A (zh) 富含γδＴ細胞的新穎組合物，及其製備方法及用途

Legal Events

Date Code Title Description
AS Assignment

Owner name: KYOTO UNIVERSITY, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHIKU, HIROSHI;HARADA, NAOZUMI;MURAOKA, DAISUKE;AND OTHERS;SIGNING DATES FROM 20180730 TO 20180806;REEL/FRAME:047798/0250

Owner name: MIE UNIVERSITY, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHIKU, HIROSHI;HARADA, NAOZUMI;MURAOKA, DAISUKE;AND OTHERS;SIGNING DATES FROM 20180730 TO 20180806;REEL/FRAME:047798/0250

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION